PCJ Stock Chart & Stats
€5.19
€0.00(0.00%)
At close: 4:00 PM EDT
€5.19
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.56 - €7.08
Previous CloseN/A
Volume0.00
Average Volume (3M)40.00
Market Cap
€229.62M
Enterprise Value€225.61M
Total Cash (Recent Filing)€146.83M
Total Debt (Recent Filing)€19.87M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 16, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding57,184,017
10 Day Avg. Volume120
30 Day Avg. Volume40
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.60Price Target Upside277.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.87
Revenue Forecast (FY)€45.16M
Bulls Say, Bears Say
Bulls Say
Commercial TractionRecognized revenue growth shows ZEVASKYN is progressing from development into commercial use. Continued treatment activity can broaden the revenue base, strengthen physician adoption, and provide a foundation for operating leverage as more qualified centers become productive.
Reimbursement SupportNTAP approval provides supplemental hospital reimbursement and validates the therapy’s clinical improvement through a formal CMS decision. This can reduce payment friction for eligible cases, support adoption among treatment centers, and improve the durability of the commercial launch.
Manufacturing ImprovementHigher commercial yield improves the amount of product available per patient and indicates progress from trial-scale production. Better yields can support treatment economics, reduce the frequency of unusable batches, and help margins move toward management’s stated full-capacity target.
Bears Say
Persistent Cash BurnHeavy negative operating and free cash flow shows that current commercialization has not yet funded the business. Unless losses narrow materially, Abeona may remain dependent on external financing, which can constrain strategic flexibility and dilute the benefits of future growth.
Manufacturing And Revenue VolatilityNonbillable batches create a direct connection between manufacturing execution and reported revenue, while the company still absorbs associated costs. Repeated yield or specification failures could delay patient treatments, weaken margins, and make the commercial ramp difficult to forecast.
Regulatory Execution RiskThe assay issue introduces uncertainty into commercial manufacturing and regulatory execution because specifications must be revisited with the FDA. Any delay or inability to resolve the matter could contribute to additional out-of-spec batches, postponed treatments, and uneven revenue recognition.
Abeona Therapeutics News
PCJ FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was €3.56 and its highest was €7.08 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is €229.62M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 24 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Aug 13, 2026. The company reported -€0.312 earnings per share for the quarter, missing the consensus estimate of -€0.207 by -€0.105.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 57,184,017 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -€0.312 in its last earnings report, missing expectations of -€0.207. Following the earnings report the stock price went down -12.791%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in DE:PCJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€19.60 (277.59% Upside)
€19.60 (277.59% Upside)
Blogger Sentiment
Bullish
DE:PCJ Sentiment 92%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth €272.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.55%
12-Months-Change
Fundamentals
Return on Equity
-41.69%
Trailing 12-Months
Asset Growth
-27.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
PCJ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights clear commercial progress: 31% quarter-over-quarter revenue growth, expansion to 7 QTCs, 12 patients treated since launch, improved average manufacturing yields in commercial runs, a strong balance sheet ($146.8M) and a significant NTAP reimbursement win that validates the therapy. However, material operational and manufacturing challenges (one low-yield and one out-of-spec batch causing unrevenueed treatments), logistical fragility around the 84-hour shelf life, regulatory work to revisit an assay specification, and continued GAAP losses introduce meaningful near-term execution risk and revenue volatility. Management has implemented clearer reporting metrics and is pursuing operational learnings to mitigate these issues, but variability in site activation and sensitivity to manufacturing yield remain key risks to the revenue ramp.View all DE:PCJ earnings summariesPCJ Stock 12 Month Forecast
Average Price Target
€19.60
▲(277.59% Upside)